Gain Therapeutics (GANX) to Release Quarterly Earnings on Tuesday

Gain Therapeutics (NASDAQ:GANX) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Gain Therapeutics Stock Performance

Shares of NASDAQ GANX opened at $2.40 on Tuesday. The business’s 50-day moving average price is $2.23 and its two-hundred day moving average price is $2.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a one year low of $0.89 and a one year high of $4.63. The company has a market capitalization of $63.66 million, a P/E ratio of -2.18 and a beta of 0.14.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GANX shares. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Scotiabank started coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price for the company. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.